348 related articles for article (PubMed ID: 31039795)
1. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.
Löffler MW; Mohr C; Bichmann L; Freudenmann LK; Walzer M; Schroeder CM; Trautwein N; Hilke FJ; Zinser RS; Mühlenbruch L; Kowalewski DJ; Schuster H; Sturm M; Matthes J; Riess O; Czemmel S; Nahnsen S; Königsrainer I; Thiel K; Nadalin S; Beckert S; Bösmüller H; Fend F; Velic A; Maček B; Haen SP; Buonaguro L; Kohlbacher O; Stevanović S; Königsrainer A; ; Rammensee HG
Genome Med; 2019 Apr; 11(1):28. PubMed ID: 31039795
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
3. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
4. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
[TBL] [Abstract][Full Text] [Related]
5. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
6. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
7. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
8. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
[TBL] [Abstract][Full Text] [Related]
9. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
10. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
[TBL] [Abstract][Full Text] [Related]
11. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer.
Löffler MW; Nussbaum B; Jäger G; Jurmeister PS; Budczies J; Pereira PL; Clasen S; Kowalewski DJ; Mühlenbruch L; Königsrainer I; Beckert S; Ladurner R; Wagner S; Bullinger F; Gross TH; Schroeder C; Sipos B; Königsrainer A; Stevanović S; Denkert C; Rammensee HG; Gouttefangeas C; Haen SP
Front Immunol; 2019; 10():2526. PubMed ID: 31803175
[No Abstract] [Full Text] [Related]
12. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
13. Neoantigens as potential vaccines in hepatocellular carcinoma.
Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Aparicio B; Egea J; Tamayo-Uria I; Hervás-Stubbs S; García-Balduz J; Castro C; Iñarrairaegui M; Tagliamonte M; Mauriello A; Cavalluzzo B; Buonaguro L; Rohrer C; Heim K; Tauber C; Hofmann M; Thimme R; Sangro B; Sarobe P
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193931
[TBL] [Abstract][Full Text] [Related]
14. Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study.
Ding K; Wu S; Ying W; Pan Q; Li X; Zhao D; Li X; Zhao Q; Zhu Y; Ren H; Qian X
Sci Rep; 2015 Dec; 5():17564. PubMed ID: 26631547
[TBL] [Abstract][Full Text] [Related]
15. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
[TBL] [Abstract][Full Text] [Related]
16. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
[TBL] [Abstract][Full Text] [Related]
17. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
[TBL] [Abstract][Full Text] [Related]
18. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
[TBL] [Abstract][Full Text] [Related]
19. [Induction of specific CD8(+) T cells against hepatocellular carcinoma-associated neoantigens].
Wang YM; Zhao BH; Chen K; Li ZJ; Qu CF
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):429-434. PubMed ID: 31216828
[No Abstract] [Full Text] [Related]
20. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
Front Immunol; 2020; 11():373. PubMed ID: 32226429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
